Organoidsciences Ltd.
Research Organoidsciences Ltd. (476040.KQ) on Bullrun: market cap KRW 41.75B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker476040.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 41.75B
- Financial periodQ2 2026
- RevenueKRW 597.98M
- Net income-KRW 6.93B
- Free cash flow-KRW 3.94B
- Gross margin100.0%
Valuation Snapshot
latest market cap is KRW 41.75B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 41.75B | n/a | n/a | n/a |
Dividend history
About Organoidsciences Ltd.
Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Organoidsciences Ltd.'s market cap?
Organoidsciences Ltd.'s market capitalization is KRW 41.75B.
What does Organoidsciences Ltd. do?
Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea.